Microdose vs Standard GLP-1
Microdose GLP-1 starts below the standard label entry dose and ramps slowly, prioritizing GI tolerability, muscle preservation, and metabolic adaptation over speed of weight loss. Standard titration follows the manufacturer's label ramp. Both require provider oversight; the choice is candidacy-driven, not preference-driven.
Microdose is the provider-reviewed approach when GI tolerability, muscle preservation, older-adult context, or a slower sustainable trajectory matter more than speed of loss.
Standard titration is appropriate when the candidate tolerates the manufacturer ramp and a faster trajectory aligns with goals and supervision.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Does microdosing reduce efficacy?
It reduces speed of weight loss in the short window, not the molecule's mechanism. Many candidates reach durable outcomes with materially better tolerability.
Is microdose only for tirzepatide?
No. Microdose architecture applies to both semaglutide and tirzepatide and is provider-tuned to the molecule and patient.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment